KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Net Cash Flow (2018 - 2025)

Moderna (MRNA) has disclosed Net Cash Flow for 8 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 416.96% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $666.0 million through Dec 2025, up 166.67% year-over-year, with the annual reading at $666.0 million for FY2025, 166.67% up from the prior year.
  • Net Cash Flow for Q4 2025 was $1.5 billion at Moderna, up from -$148.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $2.8 billion in Q1 2021, with the low at -$2.2 billion in Q2 2022.
  • Average Net Cash Flow over 5 years is -$2.0 million, with a median of $65.5 million recorded in 2022.
  • The sharpest move saw Net Cash Flow surged 1705.77% in 2021, then crashed 1450.93% in 2022.
  • Over 5 years, Net Cash Flow stood at $1.3 billion in 2021, then tumbled by 86.45% to $176.0 million in 2022, then tumbled by 114.2% to -$25.0 million in 2023, then surged by 1232.0% to $283.0 million in 2024, then soared by 416.96% to $1.5 billion in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $1.5 billion, -$148.0 million, and -$346.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.